Trial Profile
A Phase 1, Open-Label, Non-Randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Vepoloxamer in Subjects With Varying Degrees of Renal Impairment and Healthy Matched Control Subjects With Normal Renal Function
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Dec 2016
Price :
$35
*
At a glance
- Drugs Poloxamer 188 (Primary)
- Indications Chronic heart failure; Myocardial infarction; Sickle cell anaemia; Stroke; Veno-occlusive disorders
- Focus Pharmacokinetics
- Sponsors Mast Therapeutics
- 20 Dec 2016 Status changed from active, no longer recruiting to completed.
- 26 Oct 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Oct 2016.
- 26 Oct 2016 Status changed from recruiting to active, no longer recruiting.